ARTICLE | Company News
Biota, GlaxoSmithKline infectious news
August 1, 2005 7:00 AM UTC
BTA is seeking A$308-A$430 million ($235-$328 million) in damages in a lawsuit against GSK for failing to support and promote BTA's inhaled influenza drug Relenza zanamavir. The loss estimates assume...